After two decades of research, Dr. Michael Abramoff successfully launched LumineticsCore-the first autonomous AI system authorized by the FDA to diagnose diabetic retinopathy without physician oversight. The case traces his journey across algorithm design, clinical validation, regulatory navigation, and the challenges of real-world adoption. It explores the interplay between technological innovation and healthcare institutions, highlighting the need to establish evaluation metrics grounded in clinical outcomes rather than physician consensus. As adoption lags despite regulatory approval, Abramoff faces decisions about which operational, reimbursement, and trust-building barriers to prioritize-decisions that may shape not only LumineticsCore's future but also the broader path of AI in medicine.